Rhumbline Advisers Acquires 17,442 Shares of Evolus, Inc. (NASDAQ:EOLS)

Rhumbline Advisers grew its holdings in Evolus, Inc. (NASDAQ:EOLS) by 27.3% in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 81,439 shares of the company’s stock after acquiring an additional 17,442 shares during the quarter. Rhumbline Advisers owned 0.13% of Evolus worth $884,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of EOLS. Perceptive Advisors LLC boosted its position in shares of Evolus by 166.8% in the fourth quarter. Perceptive Advisors LLC now owns 3,963,424 shares of the company’s stock valued at $41,735,000 after acquiring an additional 2,477,623 shares during the period. Assenagon Asset Management S.A. lifted its position in Evolus by 5,627.2% during the second quarter. Assenagon Asset Management S.A. now owns 947,103 shares of the company’s stock worth $10,276,000 after purchasing an additional 930,566 shares during the period. Lord Abbett & CO. LLC bought a new stake in Evolus during the first quarter worth about $11,628,000. Zimmer Partners LP bought a new stake in Evolus during the first quarter worth about $4,200,000. Finally, BNP Paribas Financial Markets lifted its position in Evolus by 84.2% during the first quarter. BNP Paribas Financial Markets now owns 405,931 shares of the company’s stock worth $5,683,000 after purchasing an additional 185,532 shares during the period. Institutional investors own 90.69% of the company’s stock.

Insiders Place Their Bets

In other news, CFO Sandra Beaver sold 3,276 shares of the company’s stock in a transaction that occurred on Friday, September 6th. The stock was sold at an average price of $14.98, for a total value of $49,074.48. Following the completion of the transaction, the chief financial officer now owns 148,502 shares of the company’s stock, valued at $2,224,559.96. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. In other news, CMO Tomoko Yamagishi-Dressler sold 5,631 shares of the company’s stock in a transaction that occurred on Friday, August 30th. The stock was sold at an average price of $15.85, for a total value of $89,251.35. Following the completion of the transaction, the chief marketing officer now owns 82,375 shares of the company’s stock, valued at $1,305,643.75. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Sandra Beaver sold 3,276 shares of the company’s stock in a transaction that occurred on Friday, September 6th. The shares were sold at an average price of $14.98, for a total value of $49,074.48. Following the completion of the transaction, the chief financial officer now directly owns 148,502 shares of the company’s stock, valued at approximately $2,224,559.96. The disclosure for this sale can be found here. Insiders own 6.10% of the company’s stock.

Evolus Stock Down 6.2 %

Shares of NASDAQ EOLS opened at $15.53 on Tuesday. The company has a current ratio of 2.92, a quick ratio of 2.67 and a debt-to-equity ratio of 6.26. The company has a market cap of $972.18 million, a price-to-earnings ratio of -14.79 and a beta of 1.31. Evolus, Inc. has a 12 month low of $7.44 and a 12 month high of $17.70. The stock has a 50-day moving average price of $14.35 and a two-hundred day moving average price of $13.12.

Evolus (NASDAQ:EOLS) last issued its earnings results on Wednesday, July 31st. The company reported ($0.14) EPS for the quarter, missing the consensus estimate of ($0.12) by ($0.02). The business had revenue of $66.91 million during the quarter, compared to analysts’ expectations of $65.06 million. As a group, analysts forecast that Evolus, Inc. will post -0.64 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

EOLS has been the subject of several recent analyst reports. Needham & Company LLC reaffirmed a “buy” rating and set a $22.00 price objective on shares of Evolus in a research report on Friday, September 13th. Barclays upped their price objective on shares of Evolus from $16.00 to $20.00 and gave the stock an “overweight” rating in a research report on Friday, September 13th. HC Wainwright reaffirmed a “buy” rating and set a $27.00 price objective on shares of Evolus in a research report on Thursday, August 1st. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Evolus in a research report on Monday, September 16th.

About Evolus

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.